Eli Lilly & Company finds itself at a fascinating crossroads. Despite a week marked by significant clinical progress and proposed corporate governance reforms, the pharmaceutical giant’s shares continue to trade approximately 17% below their November peak. This disconnect highlights a more nuanced investment narrative than recent headlines suggest.
Pipeline Catalysts and Competitive Dynamics
The recent Phase 3 data for Retatrutide, a triple-hormone receptor agonist, delivered strong clinical outcomes. Trial participants achieved an average A1C reduction of up to 2.0 percentage points and lost an average of 16.8% of their body weight. However, the market’s reaction was measured. Investor attention is sharply focused on the upcoming FDA decision for Orforglipron, expected on April 10. This oral GLP-1 pill represents a potentially larger commercial opportunity.
Orforglipron’s key differentiator could be its lack of restrictions regarding food and beverage intake, a limitation present with Novo Nordisk’s competing oral therapy. Novo Nordisk has already entered the market with its pill, securing a timing advantage. The April decision will clarify whether Lilly’s convenience feature can translate into meaningful market share gains in the lucrative obesity and diabetes sector.
Stellar Financial Performance Underpins Confidence
The fundamental case for Eli Lilly remains robust, as evidenced by its latest financial results. Fourth-quarter revenue surged 43% to $19.3 billion, while net income jumped 50% to $6.6 billion. The growth drivers are clear: sales of Mounjaro and Zepbound soared by 99% and 175% respectively in 2025, collectively accounting for 56% of total revenue. Looking ahead, management has set an ambitious revenue target of $80 to $83 billion for 2026, implying growth of approximately 25%.
This operational excellence is reflected in executive compensation. The company’s recent proxy filing revealed an annual bonus payout at 218% of target and three-year shareholder value awards paid at 200%. These payouts were triggered by a total shareholder return of 40%, which outperformed both the S&P 500 and a peer group over one-, three-, and five-year periods.
Should investors sell immediately? Or is it worth buying Eli Lilly?
A Responsive Governance Modernization
In a move signaling responsiveness to shareholder input, Eli Lilly has proposed substantial governance changes in its 2026 proxy statement. The company aims to eliminate its staggered board structure and remove supermajority voting requirements. If approved, these changes would mean all board directors stand for election annually and voting thresholds would be simplified.
The board, however, has recommended against two specific shareholder proposals: one calling for an independent board chair and another requesting expanded lobbying disclosure. This nuanced approach—adopting some investor-sought reforms while rejecting others—frames the governance update as a strategic evolution rather than a wholesale concession.
Divergent Analyst Views Reflect Market Uncertainties
Wall Street’s outlook on Eli Lilly shares reveals a spectrum of conviction. The current consensus price target stands just above $1,221, suggesting a potential upside of roughly 35% from recent levels. Sentiment is broadly positive, with 25 of the last 30 analyst ratings being “Buy” or equivalent.
UBS reaffirmed its $1,250 price target on March 18, citing strong Q4 results and a raised full-year outlook. In contrast, HSBC recently downgraded its rating, expressing concerns about intensifying competition within the obesity drug market. This divergence underscores that even for a company with Lilly’s momentum, perceived risks around market saturation and competitive threats are influencing valuation debates.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from March 24 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 24.
Eli Lilly: Buy or sell? Read more here...
